Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Related Citations for PubMed (Select 25066269)

1.

Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer.

O'Neil BH, Cainap C, Van Cutsem E, Gorbunova V, Karapetis CS, Berlin J, Goldberg RM, Qin Q, Qian J, Ricker JL, Fischer J, McKee MD, Carlson DM, Kim TW.

Clin Colorectal Cancer. 2014 Sep;13(3):156-163.e2. doi: 10.1016/j.clcc.2014.04.001. Epub 2014 Jun 23.

PMID:
25066269
2.

Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).

Schmoll HJ, Cunningham D, Sobrero A, Karapetis CS, Rougier P, Koski SL, Kocakova I, Bondarenko I, Bodoky G, Mainwaring P, Salazar R, Barker P, Mookerjee B, Robertson J, Van Cutsem E.

J Clin Oncol. 2012 Oct 10;30(29):3588-95. doi: 10.1200/JCO.2012.42.5355. Epub 2012 Sep 10.

3.

Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer.

Tan EH, Goss GD, Salgia R, Besse B, Gandara DR, Hanna NH, Yang JC, Thertulien R, Wertheim M, Mazieres J, Hensing T, Lee C, Gupta N, Pradhan R, Qian J, Qin Q, Scappaticci FA, Ricker JL, Carlson DM, Soo RA.

J Thorac Oncol. 2011 Aug;6(8):1418-25. doi: 10.1097/JTO.0b013e318220c93e.

PMID:
21597387
4.

PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.

Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS, Go WY.

J Clin Oncol. 2014 Jul 20;32(21):2240-7. doi: 10.1200/JCO.2013.53.2473. Epub 2014 Mar 31.

PMID:
24687833
5.

Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.

Yamada Y, Takahari D, Matsumoto H, Baba H, Nakamura M, Yoshida K, Yoshida M, Iwamoto S, Shimada K, Komatsu Y, Sasaki Y, Satoh T, Takahashi K, Mishima H, Muro K, Watanabe M, Sakata Y, Morita S, Shimada Y, Sugihara K.

Lancet Oncol. 2013 Dec;14(13):1278-86. doi: 10.1016/S1470-2045(13)70490-X. Epub 2013 Nov 11. Erratum in: Lancet Oncol. 2014 Jan;15(1):e4.

PMID:
24225157
6.

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.

Tappenden P, Jones R, Paisley S, Carroll C.

Health Technol Assess. 2007 Mar;11(12):1-128, iii-iv. Review.

8.

Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.

Ramalingam SS, Shtivelband M, Soo RA, Barrios CH, Makhson A, Segalla JG, Pittman KB, Kolman P, Pereira JR, Srkalovic G, Belani CP, Axelrod R, Owonikoko TK, Qin Q, Qian J, McKeegan EM, Devanarayan V, McKee MD, Ricker JL, Carlson DM, Gorbunova VA.

J Clin Oncol. 2015 Feb 10;33(5):433-41. doi: 10.1200/JCO.2014.55.7173. Epub 2015 Jan 5.

PMID:
25559798
9.

The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801).

Nakayama G, Uehara K, Ishigure K, Yokoyama H, Ishiyama A, Eguchi T, Tsuboi K, Ohashi N, Fujii T, Sugimoto H, Koike M, Fujiwara M, Ando Y, Kodera Y.

Cancer Chemother Pharmacol. 2012 Oct;70(4):575-81. Epub 2012 Aug 12.

10.

Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer.

Cunningham D, Wong RP, D'Haens G, Douillard JY, Robertson J, Stone AM, Van Cutsem E; HORIZON I study group.

Br J Cancer. 2013 Feb 19;108(3):493-502. doi: 10.1038/bjc.2012.545. Epub 2013 Jan 8.

11.

Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.

Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M, Kang YK, Chen PJ, Toh HC, Gorbunova V, Eskens FA, Qian J, McKee MD, Ricker JL, Carlson DM, El-Nowiem S.

J Clin Oncol. 2015 Jan 10;33(2):172-9. doi: 10.1200/JCO.2013.54.3298. Epub 2014 Dec 8.

PMID:
25488963
12.

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E.

J Clin Oncol. 2003 Jan 1;21(1):60-5.

PMID:
12506171
13.

Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.

Argilés G, Saunders MP, Rivera F, Sobrero A, Benson A 3rd, Guillén Ponce C, Cascinu S, Van Cutsem E, Macpherson IR, Strumberg D, Köhne CH, Zalcberg J, Wagner A, Luigi Garosi V, Grunert J, Tabernero J, Ciardiello F.

Eur J Cancer. 2015 Mar 24. pii: S0959-8049(15)00213-0. doi: 10.1016/j.ejca.2015.02.013. [Epub ahead of print]

PMID:
25818084
14.

Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study.

Infante JR, Reid TR, Cohn AL, Edenfield WJ, Cescon TP, Hamm JT, Malik IA, Rado TA, McGee PJ, Richards DA, Tarazi J, Rosbrook B, Kim S, Cartwright TH.

Cancer. 2013 Jul 15;119(14):2555-63. doi: 10.1002/cncr.28112. Epub 2013 Apr 19.

15.

Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.

Wagner AD, Thomssen C, Haerting J, Unverzagt S.

Cochrane Database Syst Rev. 2012 Jul 11;7:CD008941. doi: 10.1002/14651858.CD008941.pub2. Review.

PMID:
22786517
16.

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.

Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF.

J Clin Oncol. 2005 Jun 1;23(16):3697-705. Epub 2005 Feb 28.

17.

Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.

Saltz L, Badarinath S, Dakhil S, Bienvenu B, Harker WG, Birchfield G, Tokaz LK, Barrera D, Conkling PR, O'Rourke MA, Richards DA, Reidy D, Solit D, Vakiani E, Capanu M, Scales A, Zhan F, Boehm KA, Asmar L, Cohn A.

Clin Colorectal Cancer. 2012 Jun;11(2):101-11. doi: 10.1016/j.clcc.2011.05.006. Epub 2011 Nov 4.

PMID:
22055112
18.

Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.

Bendell JC, Tournigand C, Swieboda-Sadlej A, Barone C, Wainberg ZA, Kim JG, Pericay C, Pastorelli D, Tarazi J, Rosbrook B, Bloom J, Ricart AD, Kim S, Sobrero AF.

Clin Colorectal Cancer. 2013 Dec;12(4):239-47. doi: 10.1016/j.clcc.2013.09.001.

PMID:
24188685
19.

TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial.

Fuchs CS, Fakih M, Schwartzberg L, Cohn AL, Yee L, Dreisbach L, Kozloff MF, Hei YJ, Galimi F, Pan Y, Haddad V, Hsu CP, Sabin A, Saltz L.

Cancer. 2013 Dec 15;119(24):4290-8. doi: 10.1002/cncr.28353. Epub 2013 Oct 1.

20.

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.

Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, Wong L, Fehrenbacher L, Abubakr Y, Saif MW, Schwartzberg L, Hedrick E.

J Clin Oncol. 2008 Jul 20;26(21):3523-9. doi: 10.1200/JCO.2007.15.4138. Erratum in: J Clin Oncol. 2008 Oct 1;26(28): 4697.

PMID:
18640933
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk